Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sigma-Aldrich Corporation (SIAL - Analyst Report) has announced the launch of a novel scientific search engine, especially designed to offer research workers an easy access over peer-reviewed articles and abstract information on the company's website.

The new search engine enables scientists to instantly read the entire text of millions of peer-reviewed papers without any extra clicks or logins and discover applications for specific Sigma-Aldrich products in peer-reviewed literature. It is also equipped to provide free access to the Ingenuity gene and biological pathway database. This approach enhances the scientific search process and aids the research community by finding better information.

Pubget, a solutions provider which focuses on expediting the acquisition and analysis of contents, extended its technology for accessing instant full-text papers, products and technical data, along with the methods and gene data in the search tool on the Sigma-Aldrich website. This tool is handy as it allows scientists to spend more time on doing research and save time on searching.

The Ingenuity Systems Platform powers the biological search on the Sigma-Aldrich website by using the Target Explorer web services. Target Explorer provides exclusive biological content that is advanced, comprehensive and relevant to searches conducted by scientists through the Sigma-Aldrich website.

Last month, Sigma-Aldrich posted its first-quarter 2013 adjusted earnings of $1.03 per share, above the year-ago earnings of 99 cents. The results beat the Zacks Consensus Estimate of $1.00. Profit, as reported, rose roughly 4.3% year over year to $122 million (or $1.01 per share) in the quarter from $117 million (or 96 cents per share) a year ago.

Revenues rose 1.5% year over year to $675 million in the quarter, matching the Zacks Consensus Estimate. Acquisitions added 2% to sales while foreign exchange translation had a negative impact of 1%. Sigma-Aldrich’s overall end markets remained steady with improving pharma trends.

Sigma-Aldrich currently maintains a Zacks Rank #4 (Sell).

Other companies in the specialty chemical space with favorable Zacks Rank are American Pacific Corporation , American Vanguard Corp. (AVD - Snapshot Report) and Ferro Corp. (FOE - Snapshot Report). While American Pacific and American Vanguard hold a Zacks Rank #1 (Strong Buy), Ferro Corp retains a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%